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Abstract
Background: Infection with human papillomavirus (HPV) is necessary for the development of cervical carcinoma.
By contrast, the role of HPV in the pathogenesis of other malignancies, such as head and neck cancers, is less well
characterised. This study aimed to address key information gaps by conducting a systematic review and meta-analysis
of the prevalence of HPV infection in head and neck cancers, focusing on data for European populations.
Methods: MEDLINE, Embase and grey literature sources were systematically searched for primary studies that were
published in English between July 2002 and July 2012, and which reported on the prevalence of HPV infection in
head and neck cancers in European populations. Studies on non-European populations, those not published in
English, and those assessing patients co-infected with human immunodeficiency virus were excluded. Eligible
studies were combined in a meta-analysis. In addition, the potential statistical association between the head and
neck cancers and certain HPV types was investigated.
Results: Thirty-nine publications met the inclusion criteria. The prevalence of HPV of any type in 3,649 patients
with head and neck cancers was 40.0% (95% confidence interval, 34.6% to 45.5%), and was highest in tonsillar
cancer (66.4%) and lowest in pharyngeal (15.3%) and tongue (25.7%) cancers. There were no statistically significant
associations between the HPV types analysed and the geographical setting, type of sample analysed or type of
primer used to analyse samples in head and neck cancers.
Conclusions: The prevalence of HPV infection in European patients with head and neck cancers is high but varies
between the different anatomical sites of these malignancies. There appears to be no association between HPV
type and geographical setting, type of samples analysed or type of primer used to analyse samples in such cancers.
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Background
Recent evidence suggests that, in Europe, the incidence
and mortality of cancer of the oral cavity are 99.6 per
100,000 population and 44.3 per 100,000 population, re-
spectively [1]. Moreover, the World Health Organization
has estimated that, across the continent, the 5-year preva-
lence of cancers of the lip, oral cavity and pharynx is over
250,000 cases [2]. These data are part of a global disease
picture in which, each year, around 600,000 people de-
velop some form of head and neck cancer and around
300,000 die from it [3]. This condition’s diverse clinical
spectrum and the associated burden of illness, has fuelled
interest in potential aetiological factors and the extent to
which they can be prevented or modified. While risks
such as tobacco use and alcohol consumption are widely
recognised carcinogens for head and neck cancers, the
role of the human papillomavirus (HPV) in this setting
has received much less attention, until recently.
HPV can infect the stratified epithelia of the skin or
mucous membranes of the upper gastrointestinal, re-
spiratory or ano-genital tract, potentially leading to out-
comes such as genital warts and laryngeal papillomas, as
well as certain cancers. The association with cancers has
led to the various types of HPV being termed ‘low-risk’
or ‘high-risk’ depending on their known oncogenic
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potential [4]. In general, the worldwide incidence and
prevalence rates of HPV-related cancers have been ris-
ing, with studies suggesting that the risk of developing
these conditions increases with the number of lifetime
sexual partners [5-7]. HPV’s oncogenic role is most clearly
defined in cervical cancer, in which the virus is a necessary
pathogenic factor. By comparison, its aetiological contri-
bution to the other malignancies is less well characterised.
For instance, HPV is associated with only a subset of head
and neck cancers [8], with various reviews estimating
that the virus is detectable in approximately 12.8% −
59.9% of all head and neck squamous cell carcinoma
biopsies [9-12].
HPV-16 and HPV-18 are the predominant types found
in HPV-related cancers and are the main focus of
current vaccination programmes in European countries,
aimed at reducing the occurrence of HPV infection and
related cervical cancer. These programmes have been
based on vaccines that are bivalent, targeting high-risk
types with regards to oncogenic potential (HPV-16 and
HPV-18), or quadrivalent targeting both low-risk (HPV-
6 and HPV-11) and high-risk types. However, such pro-
grammes could be extended to target other oncogenic
types (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-
58), which are included in new higher-valency vaccines.
It is worth noting that available literature for European
populations has not yet quantified to what extent the
burden of illness for various head and neck cancers is
caused by high-risk HPV types. In addition, previous ana-
lyses of the benefits or cost-effectiveness of vaccination
programmes in Europe have not, in general, accounted for
cancers in sites other than the cervix [13-18].
Indeed, few recent publications have systematically
reviewed and pooled data on the overall prevalence of
HPV infections in head and neck cancers, and assessed the
presence of the specified oncogenic HPV types (i.e. HPV
etc.). Also, of five published meta-analyses that attempted
to quantify the prevalence of HPV in head and neck
cancers [9-12,19], only two reported overall pooled HPV
prevalence estimates for a European population [9,11].
The need for additional evidence on the relationship
between HPV and head and neck cancers is highlighted
by the increasing interest stakeholders in Europe have
shown in this topic. For example, the European Commis-
sion is funding major epidemiological and clinical research
in this area [20] and the role of HPV has become a key
theme of scientific conferences on head and neck cancers
[21,22]. Also, HPV-related oral cancer has been debated re-
cently in the United Kingdom (UK) Parliament [23] and
the UK Joint Committee on Vaccination and Immunisation
(JCVI) has established a HPV sub-committee, whose remit
will include examining the case for extending the national
HPV vaccination programme to help prevent head and
neck cancers associated with the organism [24,25].
Against this background, the current study aimed to
systematically review published studies to quantify the
prevalence of HPV types (specifically, 6, 11, 16, 18, 31,
33, 45, 52, and 58) in head and neck cancers, as docu-
mented within published studies on European populations
and, thereby, address key evidence gaps.
Methods
Literature search
MEDLINE, Embase and grey literature sites were system-
atically searched for potentially relevant primary studies
published between 2002 and 2012, by using words syn-
onymous with ‘human papillomavirus’, ‘HPV’, ‘prevalence’,
and ‘cancer’, combined with terms representing regions of
the head and neck (Additional file 1: Table S1 and S2).
The search terms for the anatomical regions were deliber-
ately broad because of the known variation in how the
sites of origin of HPV-related head and neck cancers have
been termed across different publications (a lack of stand-
ardisation that impedes research in this field). Publications
identified through the searches were screened using a
two-step process, comprising initial title and abstract
screening to select publications for subsequent full-text
screening. At both steps, each publication for screening
was reviewed by two researchers using pre-defined inclu-
sion criteria (Additional file 2: Table S1). Disagreements
between the researchers on the inclusion of particular
publications were resolved through discussion with a third
researcher. Figure 1 shows the flow of literature through
the search and screening process.
Data extraction and quality assessment
For each study included in the systematic review, a re-
searcher extracted data on the prevalence of HPV types
of interest (6, 11, 16, 18, 31, 33, 45, 52, and 58) in all the
head and neck cancers studied, with a view to the poten-
tial inclusion of this information in subsequent meta-
analyses. The accuracy of the data extraction was then
checked by a second researcher and, again, any discrep-
ancies between the researchers were resolved through
discussion with a third researcher.
Each study included in the systematic review was rated
for scientific quality by two independent researchers
using a modified version of the Methodological Evalu-
ation of Observational Research (MORE) criteria. This
grading tool was deemed most suitable as it was devel-
oped specifically for epidemiological studies of chronic
diseases [26] and would account for the methodological
robustness of the studies in assessing the prevalence of
HPV. However, the original MORE criteria was select-
ively adapted because almost none of the publications
reported information relevant to the criteria ‘inter-rater
reliability’ and ‘validation of the assessment/measure-
ment methods’, and so would have automatically been
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graded as low quality, thus, reducing the sensitivity of
the tool. Therefore, these two criteria were omitted and
only those remaining (the ‘modified MORE criteria’) were
applied in rating the studies for quality. Further details
of the MORE criteria are provided in Additional file 2:
Table S2).
Meta-analytic approach
A feasibility assessment was conducted to determine
whether there was sufficient evidence from the included
studies to undertake a classical meta-analysis on the
prevalence of HPV in the cancers of interest. Having con-
firmed that such an analysis was justifiable, this approach
was then used to generate a pooled estimate of prevalence
of HPV, with a 95% confidence interval (CI), for the head
and neck cancer sites of interest, both collectively and as
individual sites. Prevalence estimates were calculated as
the number of total patients (or samples) infected with the
HPV types of interest divided by the number of patients
(or samples) evaluated.
Oral and mouth cancers were treated as a single cat-
egory and this meant we analysed 10 separate head and
neck cancer categories (Table 1). Some of the data re-
ported in six studies were deemed unclassifiable, mainly
because it was not possible to separate the head and neck
cancers studied into constituent cancer types. [27-32].
Four of these publications reported some classifiable data
[27,29,30,32]. The other two studies, with no such data,
were included only in the overall pooled prevalence for
head and neck cancers [28,31]. Subgroup analysis was per-
formed only on the analysable data in these publications.
As all data used in the analysis were taken from published
sources, no ethics committee approval was sought.
Figure 1 PRISMA Diagram showing flow of literature through search and screening process.
Table 1 Number of included studies by type of cancer
Cancer Number of included studiesa
Base of tongue 5
Hypopharyngeal 5
Laryngeal 10
Oral 18
Oropharyngeal 14
Paranasal sinus 1
Pharyngeal 4
Tongue 4
Tonsillar 13
Waldeyer’s ring 2
Unclassifiable 6
aSome of the articles reported more than one type of cancer and presented
the data for each type separately, allowing the data for each type to be
regarded as a separate study. As such, the total number of articles based on
classification by cancer type does not equal the total number of included
studies in the systematic review and meta-analysis.
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Statistical methods
If the extracted HPV prevalence estimates are regarded
as constituting a random sample from a larger popula-
tion of studies, then meta-analysis of those data can be
viewed as a survey [33] in which one first obtains a ran-
dom sample of studies from a larger population of such
studies, and then from within each of these selected
studies one obtains a random sample of subjects from
the population. This two-stage sampling can be repre-
sented mathematically as follows [34]:
Ti ¼ θi þ ei Var Tið Þ ¼ τþ σi2
Where
Var is variance,
Ti is an estimate of effect size (the prevalence) for
study i,
θi is the true effect size for study i,
ei is the deviation between Ti and θi (caused by ‘sam-
pling error’),
τ is the random-effects variance,
σi
2 is the estimation, or fixed-effects variance for study i.
These equations mean that if there is no random vari-
ation in the prevalence (effect size) from study to study,
τ = 0, and all variation between the estimated prevalence
from different studies can be attributed to variation within
the sample included in the study (so-called ‘sampling
error’). This is the assumption made by so-called fixed-
effects meta-analytical (FEM) approaches. By contrast,
random-effects meta-analytic (REM) approaches allow for
the possibility that random variation between studies ac-
counts for some of the variation between their results. We
conducted the meta-analysis of HPV prevalence using
both the FEM and REM approaches because the estimates
generated were expected to reflect the presence of hetero-
geneity between the studies [35].
Each REM analysis was used to estimate the mean of
(and standard error for) θi; estimate τ; test the hypoth-
esis τ = 0 using Cochran’s Q statistic I2, a measure of the
proportion of the overall variability between study esti-
mates caused by true heterogeneity between studies [36].
Investigation of heterogeneity
Heterogeneity between the studies in this systematic re-
view might be explained by several factors [37], includ-
ing differences in study design; patient populations;
patient/sample inclusion and exclusion criteria across
studies; HPV DNA source (the type of histological sam-
ple used to test for the presence of HPV DNA), poly-
merase chain reaction (PCR) primers used to confirm
presence of the virus; and other methodological features.
Cancerous tissues can be tested for the presence of HPV
infection by either examining exfoliated cells (saline
washings; saline brushing or tissue scrapings) or fixed-
biopsy samples (formalin-fixed paraffin embedded biopsy
samples; fresh biopsy samples or frozen fixed biopsy sam-
ples), using various DNA detection techniques, such as
DNA/RNA microarray, histoimmunohistochemical stain-
ing, in-situ hybridisation, p16 immunostaining, polymer
chain reaction with or without in-situ hybridisation, signal
amplification and southern blot assay methods [38].
Therefore, to try to explain the quantitative heterogeneity
found in the pooling of the prevalence estimates, explora-
tory meta-analyses were conducted across the following
variables (chosen because of the availability of sufficient
data on these characteristics across the included studies):
 Type of samples analysed
○ Fixed biopsy
○ Others (‘other types of samples’)
 Types of primers used for the analysis
○ GP5+/GP6+ combinations
○ MY09/11 combinations (not including GP5/
GP6); others (‘other primers’)
 Geographical location of patient population or
samples
○ Eastern Europe
○ Western Europe
Exploration of statistical association between the head
and neck cancers and each HPV type
Additionally, meta-regressions were performed to deter-
mine whether any of the HPV types were particularly asso-
ciated with certain categories of head and neck cancer. As
cancer categories with fewer studies would not have had
enough data to be analysed separately, the following groups
were investigated: laryngeal, oral, oropharyngeal and tonsil-
lar cancers, with the other head and neck cancers cate-
gorised as ‘others’, for the purposes of this exploration.
Statistical analysis was performed with STATA software
(StataCorp. 2009. Stata Statistical Software: Release 12.
College Station, TX: StataCorp LP). The raw data used
in the meta-analysis are available from the authors on
request.
Results
Descriptive overview of included studies
Our systematic review identified 568 abstracts from the
search of indexed databases (MEDLINE and Embase),
once 232 duplicates had been removed. From these 568
unique citations, the full texts of 122 articles were identi-
fied and studied for their relevance to the review, using the
inclusion criteria described in Additional file 2: Table S1, in
addition to 10 articles identified from grey literature
sources. Of these, 39 articles reported on the prevalence of
the pre-specified HPV types in head and neck cancers. Fur-
ther details of included studies can be found in Additional
file 2: Table S3).
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All 39 of the publications reporting on the prevalence
of HPV types in one or more types of head and neck
cancer [27-32,39-71] related to cross-sectional or other
observational studies. Seventeen of the articles evaluat-
ing patients or samples of patients with head and neck
cancer reported on multiple cancer types and presented
the data on each type separately, allowing each of these
datasets to be regarded as a separate study [27,30,32,40,
41,43,44,50,51,53-56,58,60,67,71]. Table 1 shows the fre-
quency of included studies by cancer type.
Owing to the substantial heterogeneity between the
studies (I2: 96.3%; τ: 0.0536), sources of patient/sample
populations were categorised as being in either a Western
or an Eastern European location (see Table 2), and meta-
analysed on that basis. In general, each article included in
our analysis reported on patients or samples from only
one European country. Three articles, however, reported
on patients from multiple European countries [39,52,57],
while the geographical location of the study population or
samples was unclear in one article [54]. Table 3 shows the
distribution of included articles by country.
Fixed biopsy was the method most commonly used to
collect cancer samples to assess the prevalence of HPV
DNA, being reported as the sole collection technique in
32 articles [27-32,42-45,47-53,55,57-70]. Two articles re-
ported collection of cancer samples using exfoliating
methods [39,46], while one study used both fixed-biopsy
and exfoliating methods [41], and one used serum sam-
ples alone [71]. Three studies did not report the sample
collection method [40,54,56].
Quality assessment (using modified MORE criteria)
Most studies included in this systematic review were
graded as Level 1B and 2B (moderate to poor quality), ac-
cording to the modified MORE Levels of Evidence ratings
(scale 1A–2C, with 1A representing the highest level of
evidence) (see Table 4).
Prevalence of HPV in head and neck cancers
REM estimates should be regarded as the primary results
of the analysis because of the substantial heterogeneity
amongst the included studies. With this approach, the
overall pooled prevalence of HPV (including types 6, 11,
16, 18, 31, 33, 45, 52 and 58), as determined by the pres-
ence of viral DNA, in head and neck cancers was 40.0%
(95% CI, 34.6% to 45.5%). Estimates by type of cancer
indicated that the prevalence of HPV infections was high-
est in tonsillar cancer (66.4%; 95% CI, 57.2% to 75.6%).
The systematic review also identified two eligible studies
reporting on cancers of Waldeyer’s ring (a broader ana-
tomical category including various tonsillar and tonsil-like
tissues), the pooled prevalence of HPV for this group
was estimated to be 32.9% (95% CI, 12.7% to 53.1%)
Table 2 Geographical classification of source of patient
population/samples
Western Europe Eastern Europe
Austria, Denmark, England, Finland, France,
Germany, Greece, Hungary, Italy, Norway,
The Netherlands, Portugal, Scotland, Spain,
Sweden and the United Kingdom (UK)
Czech Republic, Lithuania,
Poland, Slovenia and
Turkey
Table 3 Number of included articles by country source(s)
of patients/samples
Country source(s) of patients/samples Number of articles
Czech Republic 3
Denmark 1
Finland 1
Finland, Norway and Sweden 1
France 1
Germany 9
Germany and Greece 1
Hungary 4
Italy 7
Lithuania 1
The Netherlands 1
Norway, Sweden and the UK 1
Poland 1
Scotland 1
Slovenia 1
Sweden 2
Turkey 1
UK 1
Unclear 1
Total 39
Table 4 Overview of quality ratings for primary studies
identified in the systematic review and meta-analysis
Modified
MORE ratinga
Modified MORE levels of evidence
definition
Number of
studiesb
1A (Good) Fewer than 4 major flaws, plus 0–1
minor flaws
3
1B (Moderate) Fewer than 4 major flaws, plus 2–3
minor flaws
17
1C (Moderate) Fewer than 4 major flaws, plus 4 or
more minor flaws
5
2A (Poor) 4 or more major flaws, plus 0–1
minor flaws
4
2B (Poor) 4 or more major flaws, plus 2–3
minor flaws
6
2C (Poor) 4 or more major flaws, plus 4 or
more minor flaws
4
aTA Shamliyan, RL Kane, MT Ansari, G Raman, ND Berkman, M Grant, G Janes,
M Maglione, D Moher and M Nasser [72].
bThe count of publications in this table includes primary studies.
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[32]. By contrast, HPV prevalence estimates were lowest
for pharyngeal cancer (15.3%; 95% CI, 3.0% to 27.7%),
and next lowest for tongue cancer (25.7%; 95% CI, 3.4%
to 47.9%). Only one study reporting on HPV types in
paranasal sinus cancer met the inclusion criteria and
this found the prevalence of HPV infection in this type
of cancer to be 60.3% (95% CI, 20.6% to 100.0%)a.
Table 5 summarises the overall prevalence of HPV and
number of patients/patient samples analysed by cancer
type. Figure 2 is a graphical presentation of the preva-
lence of HPV by cancer site.
Relationships between HPV prevalence and potential
sources of study heterogeneity
In general, there was a lack of statistically significant asso-
ciations between the prevalence of HPV infection in head
and neck and potential sources of study heterogeneity,
such as type of cancer sample analysed, type of DNA pri-
mer used to detect the virus or geographical location.
Geographical location of patient population or samples
by cancer type
The only statistically significant finding with regards to
geographic location was identified in oropharyngeal can-
cers, for which HPV prevalence was statistically lower for
Western European populations (33.7%; 95% CI, 24.2% to
43.2% vs. Eastern countries 56.9%; 95% CI, 49.5% to
64.3%). The prevalence of HPV infection in four of the
cancer groups (base of tongue, oral, pharyngeal and tonsil-
lar) was numerically, but not significantly, lower for
populations in Western Europe than in Eastern Europe.
The prevalence was numerically higher in tongue cancers
among Western European than among Eastern European
populations but, again, not significantly. Additional data
from the investigation by geographical location are pro-
vided in Table 6.
Type of samples analysed by cancer type
The estimated prevalence of HPV in oropharyngeal can-
cers was significantly lower in studies that used fixed-
biopsy samples (39.6%; 95% CI, 29.7% to 49.5%) and
other types of samples (33.3%; 95% CI, 20.4% to 46.2%)
than in the only study not reporting the type of samples
analysed (64.0%; 95% CI, 55.4% to 72.7%). The prevalence
of HPV was numerically, but not significantly, lower in
studies using fixed-biopsy samples of base of tongue and
tonsillar cancers than in those that did not report the type
of samples analysed. However, the prevalence in oral, la-
ryngeal and tongue cancers was numerically, but not sig-
nificantly, higher in fixed-biopsy samples than in other
types of samples. Additional data from the investigation
by sample type are provided in Table 6.
Types of primers used for HPV DNA analysis by cancer
type
There were no significant findings in relation to the
types of primers used for HPV DNA analysis by cancer
type. The prevalence of HPV was numerically, but not
significantly, lower in studies of tongue and tonsillar
cancer that had analysed HPV DNA types using only a
primer that included GP5+/GP6+ than in studies using
alternative primers. Also, the prevalence of HPV was nu-
merically, but not significantly, lower in studies of oral
cancers that analysed HPV DNA types either using other
types of primers or those that did not report the primers
used than those using GP5+/GP6+ primers. Addition-
ally, HPV prevalence was numerically, but not signifi-
cantly, lower in pharyngeal cancer studies that assessed
HPV DNA types using other type primers than in those
that used either GP5+/GP6+ or MY09/MY11 primers.
Additional data from the investigation by primer type
are provided in Table 6.
Meta-regression of pooled prevalence estimates of HPV
types by covariates
Meta-regressions were possible only for pooled preva-
lence estimates of the following HPV types: 6, 11, 16, 18
and 33. The covariates in these analyses were European
regional location used as covariates. As shown in Table 7,
none of the meta-regressions showed any statistically
significant association between the HPV types and the
covariates.
Discussion
The aim of this systematic review and meta-analysis was
to provide up-to-date information on the associations
Table 5 Prevalence of HPV by head and neck cancer
typea
Cancer type Number of
patients/
patient samples
tested
Prevalence
(%)
95% confidence
interval
Low (%) High (%)
Base of tongue 193 47.2 37.3 57.1
Hypopharyngeal 50 42.4 14.7 70.2
Laryngeal 498 40.0 34.6 45.5
Oral 1,157 26.6 19.8 33.3
Oropharyngeal 894 41.3 31.8 50.7
Pharyngeal 25 15.3 3.0 27.7
Tongue 113 25.7 3.4 47.9
Tonsillar 605 66.4 57.2 75.6
Waldeyer’s ring 113 32.9 12.7 53.1
All head and neck
cancers
3,649 40.0 34.6 45.5
aAggregate head and neck cancer prevalence estimates include one case of
paranasal sinus cancer with unadjusted prevalence estimates of 100.0%;
95% CI: 60.3% to 139.7% (adjusted values to reflect prevalence estimates
exceeding 100%: 60.3%; 95% CI: 20.6% to 100.0%).
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between the presence of HPV and the various head and
neck cancers in European populations, and factors that
might influence these relationships. Specifically, we
wanted to generate estimates of the prevalence of HPV
infection in the key sites of head and neck cancer. The
results of the analysis indicated that the prevalence of
HPV in such disease was high overall (at around 40%)
but also varied considerably between the different malig-
nancies, the pooled prevalence estimates for oral cancers
(18 studies), laryngeal cancer (10 studies), oropharyngeal
cancer (14 studies) and tonsillar cancer (13 studies), be-
ing 26.6%, 25.7%, 41.3% and 66.4%, respectively. All
these findings should help to address important gaps in
the literature.
The systematic review and meta-analysis were based
on data retrieved from 39 articles reporting on the
prevalence of HPV infections in head and neck cancers
in European populations and published between 2002
and 2012. This means it offers more specific and up-to-
date information than previous reviews on this topic. Of
the other five known published meta-analyses that have
quantified the prevalence of HPV in head and neck can-
cers, the first (including studies published up to 2004)
reported only on the prevalence of HPV-16 [19]; the sec-
ond included studies published up to 2004, reporting on
a total of 37 HPV types [9]; the third (and the only other
to report on a European population) estimated overall
pooled HPV prevalence but only from studies published
up to 2010 [11]; the fourth included only studies that re-
ported on HPV-16 and HPV-18 (published between
1980 to 2008) [10] and the fifth included studies up to
2007 and examined 12 HPV types [12]. While the data-
set appears to be more up-to-date than that of other
reviews, further primary studies assessing HPV preva-
lence in non-cervical cancers in European populations
continue to be published, and should ideally be incorpo-
rated in further reviews and meta-analyses on this topic.
As expected, all studies included in this review and
meta-analysis were observational in design and most
analysed populations or samples from Western (n = 16)
rather than Eastern (n = 5) Europe, according to our
geographical classification. The available data related
primarily to the more common forms of head and neck
cancer, such as disease involving the oral cavity, orophar-
ynx and larynx. By contrast, there was only one study of
cancer of the paranasal sinus (based on a single case from
a publication on a broader group of patients with head
and neck cancer), suggesting that this rare form of head
and neck cancer is comparatively under-researched with
respect to any association with HPV. Overall, the studies
included in the analysis were of poor to moderate quality
according to the modified MORE criteria.
In contrast to previous studies [9-12,19], our analysis ex-
tended the search period for evidence collection to 2012,
and identified more recent studies of Eastern European
populations [28,48,55,63], compared with another meta-
analysis which did not identify data in articles published
after 2005 [11]. Even so, the high overall prevalence of
HPV infection in head and neck cancer derived through
our analysis is similar to that reported in a recently pub-
lished meta-analysis on European populations and an
older global estimate (34.5% and 39.7%, respectively)
[11,12]. Also, while the prevalence of HPV infection across
the different categories varied widely, similar estimates to
those in our study have been reported in other meta-
analyses for populations in Europe [9,11]. In addition, the
Figure 2 Prevalence of HPV in cancers in various head and neck regions.
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Table 6 Summary of HPV prevalence by source of heterogeneity (Prevalence; 95% confidence interval)
Type of cancer Geographic location Type of samples analysed Type of primer used
Eastern Europe Western Europe Unclear Fixed-biopsy Others Not reported GP5+/GP6+ MY09/MY11
(not GP5+/GP6+)
Others Not reported
Base of tongue 50.0%; 95% CI,
23.7% to 76.3%
44.5%; 95% CI,
29.4% to 59.5%
53.7%; 95% CI,
40.9% to 66.6%
41.5%; 95% CI,
26.9% to 56.1%
Not applicable 53.7%; 95% CI,
44.6% to 62.8%
50.0%; 95% CI,
23.7% to 76.3%
Not applicable 39.5%; 95% CI,
20.2% to 58.8%
53.7%; 95% CI,
44.6% to 62.8%
Hypopharyngeal Not applicablea Not applicableb 60.0%; 95 CI%,
20.3% to 100.0%c
50.0%; 95 CI%,
21.5% to 78.5%
48.9%; 95 CI%,
0.0% to 97.9%d
29.3%; 95 CI%,
12.0% to 46.3%
Laryngeal 27.5%; 95 CI%,
0.0% to 55.1%c
28.0%; 95 CI%,
14.8% to 41.2%
Not applicable 32.0%; 95 CI%,
17.0% to 47.1%
19.7%; 95 CI%,
12.8% to 26.6%
Not applicable 25.6%; 95 CI%,
5.1% to 46.0%
56.0%; 95 CI%,
0.0% to 100.0%c,d
29.6%; 95 CI%,
4.7% to 54.7%
20.5%; 95 CI%,
14.0% to 26.9%
Oral 34.7%; 95 CI%,
9.4% to 60.0%
21.3%; 95 CI%,
15.0% to 27.7%
Not applicable 27.5%; 95% CI,
20.3% to 34.8%
26.6%; 95% CI,
19.8% to 33.3%
Not applicable 34.8%; 95 CI%,
17.6% to 52.0%
34.5%; 95 CI%,
14.2% to 54.8%
16.9%; 95 CI%,
0.0% to 34.6%c
16.7%; 95 CI%,
0.0% to 34.6%c
Oropharyngeal 56.9%; 95% CI,
49.5% to 64.3%
33.7%; 95% CI,
24.2% to 43.2%
Not applicable 39.6%; 95% CI,
29.7% to 49.5%
33.3%; 95% CI,
20.4% to 46.2%
64.0%; 95% CI,
55.4% to 72.7%
46.8%; 95 CI%,
33.2% to 60.3%
36.5%; 95 CI%,
0.0% to 73.1%c
37.8%; 95 CI%,
15.5% to 60.2%
37.7%; 95 CI%,
19.9% to 55.5%
Pharyngeal 20.0%; 95% CI,
0.0% to 49.4%c
14.3%; 95% CI,
0.7% to 27.9%
Not applicable Not applicableb 29.4%; 95 CI%,
0.0% to 58.8%c
29.4%; 95 CI%,
0.0% to 58.8%c
22.1%; 95 CI%,
0.0% to 44.1%c
Not applicable
Tongue 12.2%; 95% CI,
0.0% to 24.4%
32.1%; 95% CI,
0.9% to 63.2%
Not applicable 34.2%; 95% CI,
0.0% to 68.3%
21.4%; 95% CI,
10.9% to 32.0%
Not applicable 12.2%; 95 CI%,
0.0% to 24.4%c
Not applicable 33.3%; 95 CI%,
0.0% to 100.0%c,d
21.4%; 95 CI%,
10.9% to 32.0%
Tonsillar 80.4%; 95% CI,
69.7% to 91.1%
64.2%; 95% CI,
54.1% to 74.3%
Not applicable 65.0%; 95% CI,
54.2% to 75.8%
Not applicable 73.3%; 95% CI,
65.6% to 81.1%
62.4%; 95 CI%,
43.5% to 81.3%
80.3%; 95 CI%,
68.2% to 92.4%
62.6%; 95 CI%,
30.0% to 95.1%
68.7%; 95 CI%,
61.6% to 75.8%
aAll studies investigated patients from Western Europe.
bThe sources of all cancer types were fixed biopsies.
cAdjusted values to reflect prevalence estimates less than 0.0%.
dAdjusted values to reflect prevalence estimates exceeding 100%.
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prevalence of HPV in oropharyngeal cancers in our study
was similar to that in other meta-analyses, and lower than
that found among North American populations in those
studies (47.0% [9] and 59.9% [11], respectively).
To some extent, the wide range of HPV prevalence be-
tween different cancers in our study might reflect varia-
tions in the amount of data available and, therefore, the
precision of estimates for particular cancers. In addition,
not only was the number of available studies very limited
for some of the head and neck cancer categories, there
was considerable heterogeneity among included studies,
potentially contributing to the overall wide range of HPV
prevalence. However, even allowing for such sources of
variation in the prevalence data, there still appeared to be
marked differences between those cancers for which more
data were available and the estimates therefore more pre-
cise (as suggested by their narrower CIs). Such evidence
does not establish categorically that there are differences
between head and neck cancers with regards to HPV
prevalence, for example, those suggested between oral or
pharyngeal cancers, and oropharyngeal cancers. It is pos-
sible that the results for these latter regions were random
findings from heterogeneous data, and that actual preva-
lence for the oropharyngeal region is somewhere in the
Table 7 Pooled prevalence estimates of HPV types by covariatea
HPV type Covariates Coefficient Standard error 95% confidence interval p-value
Low High
HPV-6 Western vs. Eastern −0.059 0.198 −0.609 0.492 0.782
GP5+/GP6 + b 0.124 0.171 −0.350 0.599 0.507
Laryngealc 0.040 0.136 −0.393 0.473 0.788
Oralc 0.459 0.210 −0.208 1.126 0.116
HPV-11 Western vs. Eastern −0.005 0.090 −0.393 0.383 0.960
Fixed biopsy vs. others −0.018 0.142 −1.825 1.788 0.919
GP5+/GP6 + b 0.017 0.118 −1.478 1.512 0.908
MY09/MY11b 0.032 0.169 −2.112 2.176 0.882
Laryngealc −0.014 0.160 −2.009 1.981 0.944
Oralc 0.006 0.129 −1.634 1.647 0.968
HPV-16 Western vs. Eastern 0.101 0.100 −0.105 0.308 0.320
Fixed biopsy vs. others 0.356 0.282 −0.228 0.939 0.220
GP5+/GP6 + b −0.095 0.108 −0.321 0.132 0.393
MY09/MY11b −0.066 0.161 −0.403 0.271 0.687
Laryngealc −0.171 0.155 −0.493 0.152 0.283
Oralc −0.030 0.131 −0.303 0.242 0.820
Oropharyngealc 0.183 0.133 −0.094 0.460 0.184
Tonsillarc 0.194 0.126 −0.069 0.457 0.139
HPV-18 Western vs. Eastern 0.249 0.302 −0.713 1.210 0.471
Fixed biopsy vs. others 0.191 0.407 −1.103 1.485 0.671
GP5+/GP6 + b 0.207 0.477 −1.847 2.261 0.707
MY09/MY11b −0.039 0.592 −2.587 2.509 0.954
Laryngeal^ −0.146 0.398 −1.414 1.121 0.737
HPV-33 Western vs. Eastern −0.029 0.032 −0.099 0.040 0.375
GP5+/GP6 + b −0.039 0.042 −0.132 0.056 0.390
MY09/MY11b 0.036 0.157 −0.314 0.386 0.825
Laryngealc 0.017 0.094 −0.197 0.230 0.863
Oralc −0.082 0.084 −0.272 0.108 0.354
Oropharyngealc −0.094 0.070 −0.251 0.064 0.212
Tonsillarc −0.108 0.068 −0.262 0.045 0.144
aSignificance level: p < 0.05.
bCompared with ‘other’ types of primers (not including GP5+/GP6+ or MY09/MY11 combinations).
cCompared with ‘other’ cancers (base of tongue, hypopharyngeal, paranasal sinus, pharyngeal, tongue, unclassifiable, and Waldeyer’s ring).
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range of 20%–40%. Further research is required to clarify
this issue. However, pending this, it is important to note
again that previous studies have also described differences
in HPV prevalence between various site-specific carcin-
omas [9,12,73].
Equally, however, these results caution against automat-
ically assuming that HPV has a similar pathogenic role in
these anatomically linked conditions, even though the dif-
ferences in prevalence between sites were not statistically
significant. There are, of course, other risk factors associ-
ated with particular head and neck regions that may in-
crease the overall risk of oncogenesis in these regions. For
example, smoking is more likely to affect paranasal sinuses
[74], and alcohol plus tobacco consumption the tongue
and oral cancers [75,76]. Previous work on HPV preva-
lence and head and neck cancers has stated the need
for further research to clarify the virus’ role in such
conditions, including any co-interactions with other
carcinogenic factors, such as smoking [73,77]. Such re-
search is needed to determine whether HPV prevalence
overestimates HPV's true contribution to development
of these cancers.
A secondary objective of this study was to perform
meta-regression to seek potential associations between
the presence of particular HPV types and pre-defined
covariates in the different categories of head and neck
cancer. Overall, these analyses provided no clear evi-
dence for or against such associations. This included in-
conclusive results from meta-regressions investigating
possible associations between HPV prevalence in these
cancers and the type of sample used to identify the pres-
ence of the organism. These findings are interesting given
that existing evidence has suggested that the use of exfoli-
ated cells to identify HPV infection might be an unreliable
method that has low detection rates and, therefore, gives a
misleadingly low indication of prevalence when compared
with fixed-biopsy samples [8,78].
The meta-analysis of the prevalence of HPV infection
in different head and neck cancers had various limita-
tions. Our analysis did not include all oncogenic and
non-oncogenic HPV types. However, our results provide
up-to-date data on HPV types 6, 11, 16, 18, 31, 33, 45,
52 and 58. Another limitation of our study was the lack
of high-quality studies for inclusion in the meta-analysis,
which resulted in the substantial heterogeneity identified
within the available data set. In view of the latter, we tested
potentially influential study covariates that may have
accounted for differential prevalence estimates in the HPV
types identified in the different cancers, in addition to ana-
lysing the data using fixed- and random-effects models.
However, this additional exploration did not provide
definitive evidence as to source(s) of the heterogeneity.
Other potential sources of heterogeneity not investigated
in our meta-analysis included the date the cancer samples
were taken, which could provide data on changes in HPV
prevalence in the countries evaluated. This could be also
important if, over time, demographic and other risk fac-
tors associated with head and neck cancers had changed
to different degrees in different countries. Another consid-
eration not accounted for in this analysis was the time it
takes to develop cancer, since variations in the duration
between risk factor acquisition and cancer diagnosis could
have added to heterogeneity.
The meta-regression analyses used in the study had
the potential to explore important associations between
HPV and different head and neck cancers, but were also
associated with considerable limitations. These included
difficulties relating to the meta-regression methods used
to pool prevalence estimates of HPV types by country,
types of samples analysed and primer types. To conduct
this analysis, the three independent factors of interest
(country, types of samples analysed and primer types)
were considered to be categorical. Clear categories for the
various head and neck cancers were initially sought after.
However, these efforts were complicated by the lack of in-
formation on how individual authors defined the regions
of the head and neck in their studies. Ultimately, there-
fore, the classifications reported in each of the selected ar-
ticles had to be used within our analysis.
The meta-regression approach was also limited as it is
particularly suited for outcomes that are continuous and
have values within a potentially non-limited range; this was
clearly not the case for the covariates examined in our
study. Another relevant issue with the meta-regression ap-
proach is that the standard errors of the prevalence esti-
mates (i.e., the inverse of the weights) are equal to 0 when
the HPV prevalence for a particular study is 0 or 1; and this
leads to the automatic exclusion of that specific study from
the analysis. A potential alternative analytical approach in
this context would be the use of logistic regression to in-
vestigate the presence of any associations between preva-
lence estimates and the different cancer types. However, as
with the meta-regression used in the current study, the ro-
bustness of any results could still be threatened by the lack
of data available for some of the required analyses. Finally,
it is important to note that estimation of the prevalence of
various HPV types in each of the categories of the head
and neck cancer was beyond the intended scope of our
study. Further research on this topic in European popula-
tions would be a key addition to the literature.
Current deliberations among researchers and policy-
makers in Europe, such as those of the UK Parliament
and the JCVI HPV sub-committee, show how important
and timely it is to increase understanding of the disease
burden associated with HPV. This need is particularly
pressing for head and neck cancers in the UK, where
significant epidemiological changes in these malignan-
cies are being observed [79]. In this context, we believe
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that the results of our analysis provide key data on the
prevalence of HPV infection in head and neck cancer in
European populations, information likely to be of inter-
est to a wide range of stakeholders.
Conclusions
This study indicates that the prevalence of HPV infec-
tion in people with head and neck cancers in Europe is
high but appears to vary widely between the different
cancer types. Considerable heterogeneity was found across
the studies obtained. However, there was no clear evi-
dence of an association between geographical setting, type
of samples analysed or type of primer, and HPV type in
such malignancies.
Endnote
aAdjusted values reflect prevalence estimates exceeding
100%, original values (100.0%; 95% CI: 60.3% to 139.7%).
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